Combination drug therapy for thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a combination of two drugs, tocilizumab and flupentixol-melitracen, in people with active, moderate-to-severe thyroid-associated eye disease (TED). It aims to see if this combination can reduce eye bulging, double vision, and anxiety symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have moderate-to-severe, active TED (eye bulging, double vision, or eyelid retraction with a clinical activity score of 3 or higher).
- Your thyroid hormone levels (FT3, FT4) are normal; TSH may be low or normal.
- You have a HAMA score of 14 or higher, indicating significant anxiety.
- You are willing and able to give informed consent.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This study tests an investigational drug, KHN939, for people with moderate-to-severe inactive thyroid eye disease (also called Graves' eye disease). The goal is to see if the drug can improve symptoms such as bulging eyes and double vision. Participation lasts for several months and involves regular check-ups.
This study tests a longer-term use of MHB018A for people with thyroid eye disease who did not fully respond to treatment in a previous study. It aims to see if further treatment can help improve eye bulging and other symptoms.
This trial tests a medication called IBI311 for people with inactive thyroid eye disease that still causes bothersome symptoms like double vision or trouble closing the eyes. The goal is to see if it helps improve these problems safely.
Hear when a new Thyroid Associated Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.